HOME >> BIOLOGY >> NEWS
New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin,,America's Most Devastating Diseases

SAN FRANCISCO, Calif.--Researchers at the San Francisco Veterans Affairs Medical Center and UC San Francisco have demonstrated that a type of drug known as a cysteine protease inhibitor may be highly effective against American trypanosomiasis or Chagas1 disease, which is caused by an infection with the parasite Trypansoma cruzi (T. cruzi).

Chagas is the leading cause of heart disease in Latin America and approximately 50,000 people die every year as a result of it. Once confined to Latin America, cases of Chagas1 disease have been reported in the United States. The study provides proof that this new class of protease inhibitors can be safely used in animals to treat a parasitic infection, the researchers said.

The study, published in the August 17 issue of the Journal of Experimental Medicine, reports on the treatment of 21 mice infected with lethal doses of T. cruzi. All of the treated mice were rescued from the infection. A control group of untreated mice all died within four to ten days. Some of the treated mice were followed for as long as a year with no evidence of disease or parasites.

Importantly, the cysteine protease inhibitors produced no side-effects in the animals, and there was no indication of drug resistance. According to senior author James H. McKerrow, MD, PhD, director of the National Institutes of Health-sponsored Tropical Disease Research Unit at the San Francisco VA Medical Center, and UCSF professor of pathology and pharmaceutical chemistry, the study demonstrates in mice that cysteine protease inhibitors stop T. cruzi from replicating by 3turning off2 a specific enzyme critical to the parasite1s survival -- much like aspartate protease inhibitors work against Human Immunodeficiency Virus (HIV).

Because cysteine and aspartate protease inhibitors function in similar ways, the researchers are optimistic about the drug1s safety and efficacy in humans.

While its potential as a Chagas treatment is very encouraging, perhaps
'"/>

Contact: James Larkin
jlarkin@itsa.ucsf.edu
(415) 750-6633
University of California - San Francisco
18-Aug-1998


Page: 1 2 3

Related biology news :

1. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
2. New Class Of Molecular Cues Guides Nervous System Wiring
3. University Of Kentucky Professor Teaches First Reproductive Laboratory Science Class In The United States
4. Severity Of Classic Heat Stroke Recognized
5. Rapid Progress Reported On New Class Of Anti-Cancer Drugs
6. Bacterial Protein Structure Hints At Mechanism Of A Class Of Premature Aging Diseases
7. Protease-inhibitor cocktail protects, increases anti-microbial action of promising new peptide
8. Use Of Protease Inhibitors For HIV Associated With Dramatic Rise In Oral Warts
9. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
10. HIV-Positive Injection Drug Users Often Dont Receive Protease Inhibitors And May Not Be Aware Of The Drug
11. Researchers Document Transmission Of Protease-Resistant HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/13/2018)... CITY, N.J. (PRWEB) , ... December 12, 2018 ... ... the research and advancement of regenerative cellular therapy, has announced the launch of ... new technique to a gold standard approach of aspirating a patients autologous bone ...
(Date:12/13/2018)... FRANCISCO (PRWEB) , ... December 13, 2018 , ... ... sciences, just released a must-see documentary entitled “What Researchers Need to Know ... Reproducibility Issues in Life Science Research series. The goal of this film is ...
(Date:12/6/2018)... ... December 06, 2018 , ... ... instruments, consumables and laboratory contract services, throughout his career. During his recent five-year ... US Sales team and established the commercial laboratory operations in Brunswick, Maine. Through ...
Breaking Biology News(10 mins):
(Date:1/8/2019)... ... 2019 , ... The American Society of Gene and Cell Therapy’s ... committee made up of industry leaders identified by the ASGCT board of directors. In ... created to support ASGCT members designing transformative pilot studies in gene and cell therapy ...
(Date:1/4/2019)... (PRWEB) , ... January 02, 2019 , ... ... technology to detect precancer and cancer cells in blood, has been named as ... , a global biotech company developing cell therapies for cancer treatment, will use ...
(Date:12/19/2018)... FREDERICK, Md. (PRWEB) , ... December 19, 2018 ... ... solutions for Life Science, announces the validated release of Limfinity® version 7.1. The ... another important technical offering from RURO as 2018 comes to an end. , ...
(Date:12/14/2018)... EDMONTON, Alberta (PRWEB) , ... December 14, 2018 ... ... the Eye Machine Canada Inc., have been given the green light to immediately ... Age-Related Macular Degeneration (AMD). , The medical devices bureau of Health Canada has ...
Breaking Biology Technology:
Cached News: